Compare Tyson Foods, Inc. (TSN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tyson Foods, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Tyson Foods, Inc. trades at $56.06 (market cap $19.85B), while Zimmer Biomet Holdings Inc trades at $96.08 (market cap $18.55B). The key difference: Tyson Foods, Inc. and Zimmer Biomet Holdings Inc are close in size by market cap, and Tyson Foods, Inc. pays the higher dividend (3.62%). Which is the better fit depends on your goals.
| TSN | ZBH | |
|---|---|---|
Market Cap | $19.85B | $18.55B |
Sector | Consumer Staples | Health |
52-Week High | $68.75 | $107.71 |
52-Week Low | $50.72 | $79.58 |
Enterprise Value | $27.12B | $25.61B |
Dividend Yield | 3.62% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tyson Foods (TSN) trades at $55.85, down 2.29% today, reflecting bearish technical signals and mixed fundamentals. Recent Q3 2026 earnings of $0.99 per share beat estimates, but revenue missed expectations amid declining volumes. The company faces headwinds from persistent losses in its beef segment, though chicken and prepared foods remain profitable. Analyst consensus is a 'Buy' with a $68.50 price target, suggesting significant upside potential from current levels.
The outlook hinges on Tyson's ability to stabilize beef margins while leveraging strength in other segments. Investment appeal lies in its low P/S ratio of 0.36 and dividend yield, but risks include volatile commodity costs and execution challenges. Near-term performance will depend on Q3 2026 results and management's guidance update.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
